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Abstract  
Male breast cancer (MBC) is an uncommon malignancy. We have previously reported that the 
expression of the Hippo transducers TAZ/YAP and their target CTGF was associated with inferior 
survival in MBC patients. Preclinical evidence demonstrated that Axl is a transcriptional target of 
TAZ/YAP. Thus, we herein assessed AXL expression to further investigate the significance of 
active TAZ/YAP-driven transcription in MBC. For this study, 255 MBC samples represented in 
tissue microarrays were screened for AXL expression, and 116 patients were included. The 
DVVRFLDWLRQ EHWZHHQ FDWHJRULFDO YDULDEOHV ZDV YHULILHG E\ WKH 3HDUVRQ¶V &KL-squared test of 
independence (2-tailed) or the Fisher Exact test. The relationship between continuous variables was 
tested with the Pearson's correlation coefficient. The Kaplan-Meier method was used for estimating 
survival curves, which were compared by log-rank test. Factors potentially impacting 10-year and 
overall survival were verified in Cox proportional regression models. AXL was positively 
associated with the TAZ/CTGF and YAP/CTGF phenotypes (p=0.001 and p=0.002, respectively). 
Patients with TAZ/CTGF/AXL- or YAP/CTGF/AXL-expressing tumors had inferior survival 
compared with non-triple-positive patients (log rank p=0.042 and p=0.048, respectively). The 
variables  TAZ/CTGF/AXL and YAP/CTGF/AXL were adverse factors for 10-year survival in the 
multivariate Cox models (HR 2.31, 95%CI:1.02-5.22, p=0.045, and HR 2.27, 95%CI:1.00-5.13, 
p=0.050). Nearly comparable results were obtained from multivariate analyses of overall survival. 
The expression pattern of AXL corroborates the idea of the detrimental role of TAZ/YAP activation 
in MBC. Overall, Hippo-linked biomarkers deserve increased attention in this rare disease. 
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INTRODUCTION  
Male breast cancer (MBC) is a rare disease often arising in elderly men (Ruddy and Winer, 2013). 
Despite some recent molecular characterization efforts, its biology remains understudied 
(Piscuoglio, 2016; Johansson 2013; Kornegoor, 2012; Johansson, 2011; Callari, 2011; Johansson, 
2012; Fassan, 2009). Indeed, apart from hormone receptors that are frequently expressed (Anderson 
2010; Shaaban, 2012), and whose targeting represents the mainstay of medical treatment (Doyen, 
2010; Eggemann, 2013; Zagouri, 2013a; Zagouri, 2013b; Di Lauro, 2013; Di Lauro, 2014; Di 
Lauro, 2015), little is known about the nature of deregulated molecular networks underlying the 
disease. Coherent with the paucity of data available so far, both in terms of biological processes and 
therapeutic targets, the European Organization for Research and Treatment (EORTC) has launched 
an initiative dedicated toward obtaining a better understanding of the disease (EORTC 10085, 
available at: http://www.eortc.org/research-groups/breast-cancer-group/ongoing-and-future-
projects/).    
Over the past years, an Italy-UK collaboration was set off with the aim of investigating specific 
oncogenic pathways in MBC, and their relationship with clinical-pathological features and survival 
outcomes. On the basis of our preclinical experience, the focus was placed on signals connected 
with cancer stem cells (CSCs), a rare cellular subset whose hallmarks include self-renewal, ability 
to propagate the tumor in animal models, and resistance to current anticancer therapies (Beck and 
Blanpain, 2013). The evolutionary conserved Hippo signaling pathway was chosen for proof-of-
principle studies, considering that both our group and others demonstrated that TAZ/YAP-mediated 
gene transcription is associated with the retention/acquisition of stem-like features, self-renewal, 
epithelial-mesenchymal transition, chemoresistance and metastatic dissemination in breast CSC 
(BCSC) models (Bartucci, 2015; Cordenonsi, 2011; Xiang, 2014; Chang, 2015; Nandy, 2015). 
Moreover, our proof-of-concept clinical studies connected the expression of TAZ/YAP to inferior 
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therapeutic and survival outcomes in female breast cancer patients who received neoadjuvant 
therapy (Vici, 2014; Vici, 2016). 
+LSSRLVD³WZRIDFH´SDWKZD\, composed by two modules that, in a neoplastic background, elicit 
opposite biological outcomes (Johnson and Halder, 2014). While core kinases (MST1/2 and 
LATS1/2) and adaptors (SAV1 and MOB1A/1B) act as tumor suppressors by mediating nuclear 
exclusion, cytoplasmic retention and proteasomal degradation of the Hippo transducers TAZ/YAP, 
these, together with their DNA binding platform chiefly consisting in TEAD factors, have been 
extensively connected with tumor-promoting functions (Johnson and Halder, 2014). Many tumors 
exhibit defective activation of core Hippo kinases/adaptors, and/or  activation of upstream or lateral 
signals that, albeit not canonically placed within the pathway architecture, can directly activate 
TAZ/YAP (Piccolo, 2014).   
In MBC, we have previously reported that the expression of TAZ/YAP and their established target 
CTGF conferred inferior survival outcomes (Di Benedetto, 2016a). To provide further insights into 
the oncogenic role of TAZ/YAP in such an uncommon tumor, we herein assessed AXL, a member 
of the TAM family of receptor tyrosine kinases (RTKs) (Graham, 2014), as the Axl gene is a direct 
target of the Hippo transcriptional machinery (Azzolin, 2014; Zanconato, 2015). In turn, compelling 
evidence demonstrated that AXL mediates a variety of oncogenic functions, spanning from cancer 
cell survival to therapeutic resistance (Graham, 2014), and AXL expression has been reported in a 
number of hematological and epithelial malignancies (Wu, 2014). Overall, the present study was 
designed with the goals of i) describing the expression pattern of AXL, and ii) providing further 
ground on the clinical potential of Hippo-related biomarkers in MBC. 
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MATERIALS AND METHODS 
Study Participants and procedures 
For this retrospective analysis samples from 255 histologically confirmed, non-metastatic MBC 
patients, represented in tissue microarrays (TMAs) (Shaaban, 2012), were immunostained for 
evaluating the expression of AXL. Eligibility was assessed based on the following criteria: i) 
complete data on AXL, ii) complete data on TAZ, YAP and CTGF, iii) complete data on the 
following routine clinical-pathological features: histology, tumor grade, hormone receptors (ER, 
PgR) and Ki-67, and iv) availability of survival data. On this basis, 116 patients were included. 
Nodal status was not considered among the inclusion criteria, given that this information was 
available for 87 patients only. As already specified, tamoxifen was the most commonly 
administered agent in the adjuvant setting, albeit complete information pertinent to post-surgical 
therapy were not available (Shaaban, 2012). This study was conducted in accordance with the 
Declaration of Helsinki and approved by the Institutional Review Board RI WKH ³5HJLQD (OHQD´
National Cancer Institute of Rome and by the Leeds (East) Research Ethics Committee 
(06/Q1205/156). Samples were anonymised to the research team and informed consent was not 
required (Shaaban, 2012). This study adheres to the REMARKS guidelines (McShane; 2006). 
Immunohistochemistry 
TMAs were built from formalin-fixed paraffin-embedded (FFPE) material (Shaaban, 2012). The 
immunohistochemical assessment of AXL was performed using the polyclonal antibody anti-AXL 
(HPA037422, Sigma-Aldrich, St. Louis, USA) at the dilution of 1:200. AXL expression was 
determined both in terms of staining intensity on a four-grade scale (0: negative, 1+: weak, 2+: 
moderate, 3+: strong) and percentage of tumor-expressing cells (0-100%). Samples were considered 
positive if RIQHRSODVWLFFHOOVH[KLELWHGDGLVWLQFWmembranous/cytoplasmic immunoreactivity 
of any intensity. This cutoff reflected the lowest percentage of AXL-expressing cells observed in 
this cohort (range 30-90%). Two investigators (ADB and MM) evaluated immunoreactivity. The 
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modalities used for assessing TAZ, YAP, CTGF, hormone receptors and Ki-67 levels were detailed 
elsewhere (Shaaban, 2012; Di Benedetto, 2016a). 
Statistical analysis 
The relationship between categorical variables was assessed with tKH3HDUVRQ¶V&KL-squared test of 
independence (2-tailed) or the Fisher Exact test. The Pearson's correlation coefficient was used to 
establish the correlation between continuous variables. Survival curves were estimated and 
compared with the Kaplan-Meier method and log-rank test, respectively. Overall survival (OS) was 
calculated as the time from diagnosis to death due to any cause. For 10-year survival analysis, 
patients who experienced the outcome of interest after this time point were censored. Potential 
predictors of 10-year and overall survival were verified in uni- and multivariate Cox proportional 
regression models. The final multivariate models were built by adjusting for standard clinical-
molecular variables (invasive ductal carcinoma (IDC)/invasive lobular carcinoma (ILC) vs other 
histotypes, G3 vs G1-2, ER+/PgR+ vs other, Ki-67 high vs Ki-67 low) independently on whether 
these factors were significant at the univariate assessment. Statistical significance was set at p<0.05. 
Statistical analyses were carried out using SPSS software (SPSS version 21, SPSS Inc., Chicago, IL, 
USA).   
RESULTS  
Association between AXL expression and clinical-pathological factors 
For this study, 255 MBC samples were screened for the expression of AXL and, based on the 
aforementioned eligibility criteria, 116 patients were included in the final analysis. Representative 
immunohistochemical staining is presented in Figure 1.  Baseline characteristics of the patients who 
met the eligibility criteria are summarized in Table 1. As shown in Table 2, we did not observe any 
significant association between AXL and standard clinical-pathological factors, namely histology, 
nodal status, tumor grade, hormone receptor status, Ki-67. Conversely, AXL was positively 
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associated with the TAZ/CTGF and YAP/CTGF phenotypes (chi2 p=0.001 and p=0.002, 
respectively, as reported in Table 2). Moreover, a significant positive correlation, in terms of 
percentage of tumor-expressing cells, was seen between AXL and CTGF (Pearson's correlation 
coefficient=0.285; p=0.002, data available upon request).  Overall, these data support our 
hypothesis of active TAZ/YAP-driven gene transcription in a subset of MBC patients.  
 
Relationship between the TAZ/CTGF/AXL and  YAP/CTGF/AXL phenotypes and clinical 
outcomes  
Patients whose tumors had a triple-positive phenotype (TAZ/CTGF/AXL or YAP/CTGF/AXL) 
experienced shorter survival compared with their negative counterparts (log rank p=0.042 
and p=0.048, respectively. Figure 2, panel A and B), analogously to the TAZ/CTGF and 
YAP/CTGF models that we previously connected with inferior survival outcomes. Results from the 
univariate regression analyses, presented in Table 3, performed for identifying variables impacting 
10-year survival confirmed that the TAZ/CTGF/AXL and YAP/CTGF/AXL phenotypes  are 
adverse prognostic indicators (HR 2.37, 95%CI: 1.05-5.34, p=0.038, and HR 2.31, 95%CI:1.02-
5.22, p=0.044, respectively). The multivariate Cox models (Table 3) confirmed these data 
(TAZ/CTGF/AXL: HR 2.31, 95%CI: 1.02-5.22, p=0.045. YAP/CTGF/AXL: HR 2.27, 95%CI:1.00-
5.13, p=0.050). Nearly comparable results, even though with a trend toward statistical significance, 
were obtained in the multivariate Cox models for overall survival (TAZ/CTGF/AXL: HR 2.19, 
95%CI: 0.97-4.94, p=0.058. YAP/CTGF/AXL: HR 2.16, 95%CI:0.96-4.87, p=0.063) (Table 4).  
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DISCUSSION 
The present study aimed at providing further evidence supporting the negative prognostic 
significance of active TAZ/YAP-mediated gene transcription in MBC patients. To this end, 116 
MBC samples, previously characterized for the expression of TAZ, YAP and CTGF (Di Benedetto, 
2016a), were immunostained for AXL, another established target of the Hippo transducers. The 
message conveyed by the present study is that: i) AXL expression is significantly associated with 
the TAZ/CTGF and YAP/CTGF phenotypes, and positively correlated with CTGF, an established 
TAZ/YAP target gene, ii) patients whose tumors harbored the TAZ/CTGF/AXL and 
YAP/CTGF/AXL molecular backgrounds had adverse survival outcomes compared with patients 
whose tumors did not show molecular evidence of TAZ/YAP activation, and iii) the prognostic 
significance of the triple-positive model herein investigated was comparable to that of the 
previously described TAZ/CTGF and YAP/CTGF models, further enforcing the hypothesis that 
deregulation of the Hippo machinery may represent an important source of oncogenic stimuli in 
MBC.  
We acknowledge that, being retrospective in nature, our study has some limitations, chiefly the fact 
that we were unable to consider cancer-specific events owing to the lack of complete information 
related to the cause of death, as discussed elsewhere (Di Benedetto, 2016a). Nevertheless, ten-year 
survival is a suitable endpoint to overcome this drawback, when considering that MBC is a disease 
of elderly men and with a long natural history, comparable to that of luminal-type breast cancer 
arising in post-menopausal women (Ruddy and Winer, 2013).  Overall, our analyses at an 
intermediate time point (10-year survival) conveyed the message that deregulated Hippo pathway is 
involved in the genesis of MBC, analogously to earlier preclinical and clinical reports in female 
breast cancer (Maugeri-Saccà, 2015).  
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Next, our interest towards the Hippo pathway in MBC extends beyond the analysis of key pathway 
components. Indeed, we are currently analyzing other pathways intersecting the Hippo cascade at 
various levels. Bearing in mind the number of molecular signals interacting with the Hippo cascade 
(Piccolo, 2014), we focused our attention on the following: i) the mevalonate pathway and, ii) the 
DNA damage repair (DDR) machinery. Evidence of metabolic control of the Hippo pathway 
stemmed from a high-throughput screening of Food and Drug Administration (FDA)-approved 
compounds performed in the attempt of identifying TAZ/YAP modulators through a drug 
repositioning approach. This screening identified both hydrophilic and lipophilic statins,  a class of 
widely prescribed cholesterol-lowering medications, as the most potent TAZ/YAP modulators. 
Mechanistically, it was demonstrated that the mevalonate pathway promotes TAZ/YAP activation 
via the production of geranylgeranyl pyrophosphate (GGPP), which is essential for correct 
membrane localization, and consequently activation, of Rho GTPases (Sorrentino, 2014). These, in 
turn, inhibit TAZ/YAP phosphorylation independently on the activity of core Hippo pathway 
kinases (LATS1/2). Interestingly, the effects of statins were reproduced with the administration of 
nitrogen-containing bisphosphonates, such as zoledronic acid, a class of compounds that inhibit 
farnesyl pyrophosphate synthase, another key enzyme in the mevalonate cascade (Sorrentino, 
2014). Overall, the preclinically documented metabolic control of TAZ/YAP operated by the 
mevalonate pathway, together with the association between obesity and MBC, makes the 
mevalonate pathway an attractive therapeutic target in MBC (Humphries, 2015). Our results  
indicates that 3-Hydroxy-3-methylglutharylcoenzyme A reductase (HMG-CoAR), the rate-limiting 
enzyme of the mevalonate cascade and the target of statins (Buhaescu and Izzedine, 2007), is 
significantly co-expressed with Hippo transducers, suggesting that the mevalonate pathway 
regulates the activity of TAZ/YAP (Di Benedetto, 2016b). When reanalyzing this association in 
light of the data on AXL herein presented, we confirmed that HMG-CoAR is positively associated 
with both the TAZ/CTGF/AXL and YAP/CTGF/AXL phenotypes (Fisher Exact test p=0.024 and 
p=0.014, respectively). Regarding the DDR, a wave of preclinical evidence connected key 
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orchestrators of the DDR network, namely ATM and ATR, with the Hippo pathway (Pefani DE and 
O'Neill, 2016). In a greater detail, Hippo pathway kinases are targeted by the ATM/Chk2 and 
ATR/Chk1 pathways, thus participating in an array of interconnected biological processes spanning 
from cell-cycle checkpoint activation and replication fork stability to DNA repair and apoptosis 
(Pefani DE and O'Neill, 2016). The molecular cooperation between the Hippo pathway and the 
molecular network safeguarding genome integrity is further enforced when considering the 
interactions between Hippo pathway components and p53. Indeed, it was demonstrated that LATS2 
stabilizes p53 (Ganem NJ, 2014), and that LATS1/2 silencing shifted p53 function toward an 
oncogenic (gain-of-function), mutant-like state (Furth N, 2015). Moreover, YAP physically 
interacts with mutant p53 proteins promoting the aberrant expression of cell cycleǦrelated genes (Di 
Agostino S, 2016). Our group initiated characterization of the ATM-Chk2 and ATR-Chk1 axes in 
MBC, with the aim of providing novel information on DNA repair-linked biomarkers and their 
connection with the Hippo machinery and metabolic avenues.  
We believe that our efforts toward achieving a better comprehension of the molecular basis of MBC 
potentially hold important therapeutic implications. Indeed, inhibition of the Hippo transducers 
TAZ/YAP was preclinically obtained with various Food and Drug Administration- (FDA) approved 
compounds, such as statins, bisphosphonates, verteporfin, dobutamine, metformin, and dasatinib 
(Sorrentino, 2014; Frangou, 2014; Rosenbluh, 2012; Liu-Chittenden, 2012; Yu, 2014;  Bao, 2011; 
Wang, 2014; DeRan, 2014 ). In our opinion, agents targeting the mevalonate pathway (e.g. statins 
and nitrogen-containing bisphosphonates) and glucose-lowering compounds (e.g. metformin) are 
those for which it is plausible gathering retrospective, hypothesis-generating data. Indeed, a non-
negligible fraction of MBC patients supposedly received these treatments for co-existing medical 
conditions, such as elevated cholesterol levels, osteoporosis and diabetes, since these comorbidities 
are fairly common in elderly men. Reconsidering survival outcomes of MBC patients in light of the 
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use of these agents, target expression, and activation of the TAZ/YAP-mediated oncogenic program 
is a strategy to be pursued.   
In summary, by analyzing AXL, an established target of TAZ/YAP widely exploited in the 
preclinical setting as a proxy of their activation, we herein provided further evidence to the 
detrimental role of activated Hippo transducers in MBC. Furthermore, ongoing investigations will 
shortly help elucidate the connection between Hippo and other oncogenic signals. 
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Figure Legends 
Figure 1: Representative examples of immunohistochemical expression of AXL, TAZ, YAP and 
CTGF in MBC samples. Panels a-b-c show a sample with cytoplasmic AXL expression (a) 
cytoplasmic/nuclear TAZ (b) and cytoplasmic CTGF (c). In panels d-f, a tumor case with 
cytoplasmic AXL expression (d), cytoplasmic/nuclear YAP (e) and cytoplasmic CTGF (f). Scale 
EDUȝP Magnification 40x. Inset magnification 10x.  
Figure 2: Kaplan-Meier survival curves of overall survival regarding: (A) TAZ/CTGF/AXL and 
(B) YAP/CTGF/AXL (N=116). 
 
 
 Table 1: Baseline characteristics of MBC patients characterized for the expression of AXL (N=116) 
  
Abbreviations: ER: estrogen receptor, IDC: invasive ductal carcinoma, ILC: invasive lobular 
carcinoma, PgR: progesterone receptor. 
* ER+/PgR-  (N=15), ER-/PgR- (N=2) 
Characteristics 
 
 N (%) 
 
Age at diagnosis Median (min-max) [IQ range] 67 (34-88) [59-75] 
 
Histology IDC/ILC  101 (87.1) 
 
Other  15 (12.9) 
 
Grade G1-2 57 (49.1) 
 
G3 59 (50.9) 
 
Nodal status Positive 50 (43.1) 
 
Negative 37 (31.9) 
 
Unknown  29 (25.0) 
 
Hormone Receptors Positive (ER+/PgR+) 99 (85.3) 
 
Other* 17 (14.7) 
 
Ki-67 High ( 51 (44.0) 
 
Low (<14%) 65 (56.0) 
 
TAZ/CTGF Positive 43 (37.1) 
 
Negative 73 (62.9) 
 
YAP/CTGF Positive 48 (41.4) 
 
Negative 68 (58.6) 
 
AXL Positive 37 (31.9) 
 
Negative 79 (68.1) 
Table 2: Association between AXL, clinical-pathological factors and expression of the TAZ/CTGF 
and YAP/CTGF phenotypes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ER: estrogen receptor, IDC: invasive ductal carcinoma, ILC: invasive lobular 
carcinoma, PgR: progesterone receptor. 
* Fisher's Exact Test 
 
 
 
  AXL Chi2 Test 
  Positive Negative p-value 
  N(%) N(%)  
Histology IDC/ILC  32 (31.7) 69 (68.3)  0.999* 
 Other 5 (33.3) 10 (66.7) 
 
 
Grade G1-2 14 (24.6) 43 (75.4) 0.096 
 G3 23 (39.0) 36 (61.0) 
 
 
Nodal status Positive 18 (36.0) 32 (64.0) 0.666 
 Negative 15 (40.5) 22 (59.5) 
 
 
Hormone Receptors ER+/PgR+ 31 (31.3) 68 (68.7) 0.745 
 Other 6 (35.3) 11 (64.7) 
 
 
Ki-67 High 17 (33.3) 34 (66.7) 0.769 
 Low 20 (30.8) 45 (69.2) 
 
 
TAZ/CTGF Positive 22 (51.2) 21 (48.8) 0.001 
 Negative 15 (20.5) 58 (79.5) 
 
 
YAP/CTGF Positive 23 (47.9) 25 (52.1) 0.002 
 Negative 14 (20.6) 54 (79.4)  
Table 3: Uni- and multivariate Cox regression models  for 10-year survival  ( N=116) 
 
  Univariate Cox  
regression model 
Multivariate Cox 
regression model 
Multivariate Cox 
regression model 
  HR 
(95%CI) p-value 
HR 
(95%CI) 
p-value HR 
(95%CI) 
p-value 
Histology IDC/ILC vs other 1.20 
(0.36-3.96) 
0.762 
1.00 
(0.30-3.34) 
0.994 
1.02 
(0.30-3.42) 
0.977 
Grade G3 vs G1-2 1.84 
(0.89-3.80) 
0.099 
1.69 
(0.79-3.60) 
0.175 
1.70 
(0.80-3.63) 
0.169 
Hormone 
Receptors 
ER+/PgR+ vs other       0.66 
(0.28-1.54) 
0.335 
0.71 
(0.29-1.71) 
0.447 
0.71 
(0.29-1.71) 
0.448 
Ki-67 High vs Low 1.18 
(0.58-2.39) 
0.655 
1.13 
(0.54-2.38) 
0.737 
1.13 
(0.54-2.36) 
0.753 
TAZ/CTGF/AXL TAZ/CTGF/AXL vs 
other 
      2.37 
(1.05-5.34) 
0.038 
2.31 
(1.02-5.22) 
0.045   
YAP/CTGF/AXL YAP/CTGF/AXL vs 
other 
      2.31 
(1.02-5.22) 
0.044   
2.27 
(1.00-5.13) 
0.050 
 
Table 4: Univariate and multivariate Cox regression models for overall survival  (N=116).  
 
  Univariate Cox  
regression model 
Multivariate Cox 
regression model 
Multivariate Cox 
regression model 
  HR 
(95%CI) p-value HR (95%CI) 
p-value HR (95%CI) p-value 
Histology IDC/ILC vs other 1.30 
(0.40-4.29) 
0.662 
1.11 
(0.33-3.70) 
0.871 
1.13 
(0.34-3.77) 
0.848 
Grade G3 vs G1-2 1.94 
(0.94-3.97) 
0.071 
1.85 
(0.88-3.91) 
0.106 
1.86 
(0.88-3.93) 
0.103 
Hormone 
Receptors 
ER+/PgR+ vs other      0.76 
(0.32-1.76) 
0.519 
0.85 
(0.35-2.04) 
0.718 
0.85 
(0.35-2.04) 
0.719 
Ki-67 High vs Low 1.09 
(0.54-2.18) 
0.805 
1.01 
(0.49-2.08) 
0.982 
1.00 
(0.48-2.07) 
0.995 
TAZ/CTGF/AXL TAZ/CTGF/AXL vs 
other 
      2.26 
(1.01-5.08) 
0.048 
2.19 
(0.97-4.94) 
0.058   
YAP/CTGF/AXL YAP/CTGF/AXL vs 
other 
      2.21 
(0.98-4.97) 
0.054   
2.16 
(0.96-4.87) 
0.063 
 


